Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    16014882 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Erlotinib;   Drug: Bevacizumab
2 Active, not recruiting Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
Condition: Non-Small-Cell Lung Carcinoma
Intervention: Drug: OSI-774 (Tarceva)
3 Completed OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-small-cell Lung
Intervention: Drug: Tarceva (erlotinib HCl, OSI-774 )
4 Active, not recruiting Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
Conditions: Adenocarcinoma;   Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
5 Completed Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
Condition: Thoracic Neoplasms
Interventions: Drug: erlotinib;   Drug: gefitinib
6 Withdrawn Erlotinib for Treatment of Psoriasis
Condition: Psoriasis
Interventions: Drug: erlotinib;   Other: placebo tablet
7 Completed A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: sunitinib and rapamycin (Drug will be held)
8 Active, not recruiting Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Aprepitant and placebo;   Drug: desloratadine and placebo
9 Completed Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Erlotinib;   Drug: Docetaxel
10 Unknown  Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient
Conditions: Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent;   No EGFR Activating Mutation
Interventions: Radiation: 18F-FLT-TEP;   Radiation: 18F-FDG-TEP
11 Unknown  Tarceva Italian Lung Optimization tRial
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Erlotinib;   Drug: Docetaxel
12 Recruiting Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy
Conditions: Osteosarcoma;   Metastasis
Intervention: Drug: apatinib
13 Unknown  Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype
Condition: Lung Cancer
Intervention: Other: Characterise the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotypes
14 Unknown  Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Docetaxel
15 Withdrawn A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)
Condition: Lung Cancer
Intervention: Drug: BIBW 2992 (Afatinib)
16 Completed Erlotinib and Temsirolimus for Solid Tumors
Condition: Solid Tumors
Interventions: Drug: Erlotinib;   Drug: Temsirolimus
17 Unknown  Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib;   Procedure: FDG-/FLT-PET
18 Terminated
Has Results
Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction
Conditions: Esophageal Neoplasms;   Esophageal Diseases
Interventions: Drug: Erlotinib;   Drug: Avastin

Study has passed its completion date and status has not been verified in more than two years.